How AI Teammates Are Transforming HR Operations

BY Emily McCrary-Ruiz-Esparza | June 27, 2025

HR teams are about to expand, according to Jim Barnett, founder and CEO of Wisq. Pretty soon, our teams will comprise both human and AI colleagues, the latter taking on the tedium and grunt work HR was once famous for, while the former, the real humans, will be free to focus on people, on strategy, and on human connection.

Barnett spoke in a From Day One webinar about how AI teammates are reshaping HR operations, offering a detailed look at how agentic AI is driving that transformation. Formerly the CEO of AltaVista, one of the web’s first search engines, Barnett also has impressive HR tech credentials. He co-founded the employee success platform Glint, which was acquired by LinkedIn, and later served as LinkedIn’s head of product. With his newest venture, Wisq, he’s built an agentic AI HR generalist for enterprise teams. Her name is Harper. 

To develop Harper, Barnett logged hours with HR leaders across companies, big and small, studying what they need most. “I heard the same thing over and over: that the HR team was overwhelmed,” he said. “They were under a lot of pressure to improve the efficiency of the team. They were flooded with tickets and a lot of repetitive tasks. And we really said to ourselves, ‘How might we use AI to automate a lot of these non-strategic, repetitive tasks?’” 

And so he did. “Harper can answer 80% of HR requests for information. She can coach your teams on how to develop and grow and handle situations,” said Barnett. “She can handle policy automation and policy compliance.”

Jim Barnett, the CEO and co-founder of Wisq, pictured, spoke with journalist Emily McCrary-Ruiz-Esparza during the webinar (company photo)

When HR teams aren’t bogged down with the tedium of managing problems like absenteeism, they can spend time on more strategic projects, like talent development. “There’s no question: There’s going to be a shift. There are going to be some changes in roles,” he said.

The rote tasks of HR are often shouldered by the lowest on the ladder, but entry-level jobs won’t evaporate, Barnett says. “That’s the next generation of great HR leaders. It’s just the things that they’ll be doing will be more creative, less repetitive, and more strategic.”

So, let’s start freeing up their time. Policy compliance is something they can already hand over to an AI HR generalist. 

At one of Wisq’s clients, a large manufacturing company, 85% of their HR generalists’ time was spent on just two things: time and attendance and safety. Barnett thought Harper could do better.

“It might be the first time somebody’s been late, or they’ve been late twice, but they’ve never had any type of verbal warning or verbal discussion,” he said. Wisq found that in roughly half of those instances, Harper was able to flag that it’s too early for an HR intervention and coach the manager on what they should do instead. And if it does come time to involve HR, Harper can help them with the relevant paperwork.

There’s room for Harper in talent management too. Let’s say you’re writing a performance review for one of your employees, and you’re planning to give them a “meets expectations” rating. But then Harper reminds you that just 30 days ago, you had a serious conversation with that employee about their efficiency. With a simple signal, Harper can ensure that employees get clear, accurate feedback so they can avoid a performance improvement plan. And when it’s time to write goals for that employee, Harper can ensure those goals are specific, measurable, and time-bound.

Barnett believes that in the future, we’ll all be working alongside humans and AI teammates, “The change that’s coming is dramatic, and it’s coming fast,” he said. Yet he’s not cynical about AI personas taking over HR. People are far more valuable to him. “My personal life mission is to help people be happier and more successful at work, and so that’s really what I’ve dedicated my career to.”

Editor’s note: From Day One thanks our partner, Wisq, for sponsoring this webinar. 

Emily McCrary-Ruiz-Esparza is an independent journalist and From Day One contributing editor who writes about business and the world of work. Her work has appeared in the Economist, the BBC, The Washington Post, Inc., and Business Insider, among others. She is the recipient of a Virginia Press Association award for business and financial journalism.

(Photo by ismagilov/iStock)

Related Stories

The Real Impact of AI on Hiring: Staying Ahead of the Curve

“This pressure to do more with less can be really challenging, let alone when you start to bring in a lot of what we’re seeing today in spam and in fraud,” said Meredith Johnson, chief product officer at applicant tracking platform Greenhouse. Recruiters face more than an applicant volume challenge today: They also have to sift for the highest-quality candidates who have sincere enthusiasm for the role while lazy applicants spam hundreds employers with AI-generated resumes and bad actors try to wiggle their way into companies to steal trade secrets or work on behalf of hostile nations—a problem few recruiters ever imagined they would encounter.Johnson spoke during a From Day One webinar on the impact of AI on hiring and how talent acquisition teams can stay ahead of the curve. Greenhouse is among the companies leading the charge on combating applicant fraud while preserving the candidate experience for good-faith applicants. The company recently announced its partnership with Clear to verify applicant identity and combat fraud and spam at the top of the hiring funnel. Adopting AI for Maximum ImpactFor companies that haven’t jumped on the artificial intelligence train, the good news is that the barriers to entry are low, and the easiest tools to adopt can offload some of the most time-consuming tasks. Early stages of the hiring process are ideal for AI intervention. It’s in the setup phase that TA teams often spin their wheels, Johnson said, over-polishing job descriptions or hand-tailoring candidate outreach emails one at a time. This, she noted, is a great place to start with AI.“You might send a communication that says, ‘I hope this email finds you well. We’re currently looking for individuals with these skill sets for this role, and I was really impressed with your experience in: Enter personalization token that’s drawing from all that goodness automatically for you.’” Once the recruiter reviews and signs off, that outreach is ready to roll. And when you’ve built a solid slate of candidates, recruiters can use AI to generate questions tailored to the role and most-sought-after attributes. Though this tool has been available only for a few months, Johnson said it’s their most used AI-assisted feature, with an 80% acceptance rate, “meaning that 80% of the time, our users are just accepting, without any condition, the suggested questions that are being provided.”Of course, what every recruiter hopes to find are those candidates who are not only qualified, they’re interested and able to take on a new role. Greenhouse is now using sentiment analysis to suss out the candidates that have the greatest affinity toward specific jobs. “One of the capabilities that we rolled out with the auto-generated sentiment analysis that automatically interprets and categorizes information from the prospect email, and so it can turn back results and signals to the hiring team. How interested are they? Could it potentially be bad timing?”Journalist Emily McCrary-Ruiz-Esparza moderated the discussion with Meredith Johnson of Greenhouse (photo by From Day One)The goal is to move the best matched and most engaged talent along in the hiring process. Actually hiring stand-out applicants can be a matter of a good candidate experience, which can be a differentiator for an employer, she says, especially as companies lose good candidates among a deluge of applications.Companies may be prone to using time-saved as the primary KPI when folding AI into recruitment, but most recruiters don’t just want to move faster, they want to make better hires. Prioritizing–and measuring–the candidate experience mitigates against a hiring strategy that prizes speed at all costs. “You’re starting to get into that higher altitude of a more effective process, and that’s really important,” she said. “We want to do it with speed and have a little fun, but really, we want to get a really, really good result, and that’s what matters.”Greenhouse doesn’t operate without internal guardrails. The company runs a formal AI ethics committee that reviews all their products and updates, and they’re keen on transparency into not only what the tools do, but also what models they run on. Candidates can even opt out of some features, like interview recording and AI assistants in calls.Johnson sees challenges and opportunities beyond just sourcing, but deep “into the actual meat of recruiting.” As a hiring manager, she’s using Greenhouse’s platform to build her own team, and it’s through first-hand experience that she’s testing and developing new tools.“We think about not only solving problems in this space, but doing it with purposeful delivery and placement of AI-supported and AI-assisted capabilities,” she said. “There’s lots to uncover there where we can provide more AI-assisted time saving, efficiency, and boosting experiences in the interview process.”Editor’s note: From Day One thanks our partner, Greenhouse, for sponsoring this webinar. Emily McCrary-Ruiz-Esparza is an independent journalist and From Day One contributing editor who writes about business and the world of work. Her work has appeared in the Economist, the BBC, The Washington Post, Inc., and Business Insider, among others. She is the recipient of a Virginia Press Association award for business and financial journalism.(Photo by imaginima/iStock)

Emily McCrary-Ruiz-Esparza June 24, 2025

Prioritizing People: Building Human-Centered Benefits in a Complex Healthcare Landscape

Most people don’t think of their health as a roller coaster. But Cody Fair, chief commercial officer at Noom Health, says that’s exactly what weight loss feels like for millions of Americans. “I came today to talk about roller coasters. Not the kind you ride at an amusement park, but the one that millions of Americans are on every day: the roller coaster around weight loss.”Fair’s story is personal and all too familiar. After a life-altering diagnosis in college led to 20 years of struggling with his weight, he tried everything from diets to personal trainers to meal prep to even Noom itself. “I’ve lost the same 20 pounds 20 different times,” he said. Then GLP-1 medications entered the scene, and everything changed—almost.Fair spoke about the complex and frustrating reality of weight loss and accessing GLP-1s, the new class of drugs for obesity treatment during a thought leadership spotlight at From Day One’s NYC half-day benefits conference. He recounted his personal journey as both a healthcare executive and as a patient navigating a broken system.When Fair first started taking Wegovy, the results were immediate and dramatic. “Weight was basically falling off of me,” but then came the shortage. “I would spend time every day calling pharmacies within 50 miles,” he said, trying to track down a refill. His primary care provider (PCP) bumped him to the highest dosage, warning him of side effects. “I told her, no side effect would matter to getting back to the body that I wanted. Turns out that was a lie.” Fair got so nauseated he often had to leave in the middle of board meetings. “I couldn’t go out to eat with my friends. I couldn’t go play golf.”When another drug, Zepbound, became available in Fair’s formulary, he thought the nightmare was over. But after a few months the supply would vanish, then he’d have to navigate the obstacle of prior authorization. “By the time I’m done with that, I can’t get it. It’s gone at that pharmacy.” Even when Zepbound came off shortage, a change in his company’s insurance plan reset the whole process, or he couldn’t get approved. Cody Fair of Noom Health led the thought leadership spotlight (photo by Hason Castell for From Day One)“The PBM (Pharmacy Benefits Manager) blames the PCP. The PCP blames the pharmacy. If you’ve ever seen the Spider-Man meme where they’re all pointing at each other, that is my vision of what prior authorization in healthcare in America looks like,” he said. But Fair finally found relief, not through the system, but through a colleague at Noom. He received a 90-day supply, “weight is starting to come off, energy is coming back,” he said. Still, Fair says he’s worried for when this 90-day supply runs out.Unfortunately, Fair’s experience is not a unique one. “Hundreds, if not thousands, of your employees are probably going through that same journey.” More are going through this journey across the country. “We are in a system that is broken,” he said.“This isn’t just a personal issue. This is a workforce issue.” Fair points to lower productivity and higher absenteeism. “When you struggle with your health, you're going to struggle at work. If you struggle accessing the care that you need, it's going to affect the organization overall.” Employees, Fair emphasized, “are your most valuable asset.”Noom is helping to offer a way off the ride, says Fair. The company has developed a commercial program aimed at supporting employers and their employees who feel stuck in the cycle. Noom Med with Smart RX starts by carving GLP-1s out from PBMs to bring down cost, by about $200 per script on average, he says. Employers can choose how much of that cost to cover, whether 50% or 25%.But the real value, Fair says, is in the wraparound care. “You meet with clinicians who are experts in obesity care.” Participants use Noom’s digital tools, including a purpose-built GLP-1 companion and even a body scan app that tracks fat mass and waist-to-hip ratio. “Ultimately, we believe all of these things together are how you will truly pull an ROI out of these medications,” Fair said. “And I don’t just mean your bottom line. When I take a GLP-1, I want the ROI out of it myself. Your employees want the ROI out of what they’re doing.”“What we’re advocating for is change. Investing in your employees’ health, their well-being, and their overall future,” he said. “We have the power to reshape this narrative. To create a system where no one is judged, ashamed or left behind, and where everyone has access to the care that they need.”Editor’s note: From Day One thanks our partner, Noom, for sponsoring this thought leadership spotlight. Matthew Koehler is a freelance journalist and licensed real-estate agent based in Washington, DC. His work has appeared in the Washington Post, Greater Greater Washington, The Southwester, and Walking Cinema, among others.(Photos by mediaphotos/iStock)

Matthew Koehler June 18, 2025

Breaking the GLP-1 Cost Cycle for a Healthier Workforce, Lower Costs, and Smarter Care

The American workplace faces a costly challenge: how to offer access to high-demand weight-loss medications without overwhelming benefits budgets. With monthly prices exceeding $1,000, these treatments are becoming powerful tools in talent retention strategies across corporate America.During a From Day One webinar, Cody Fair, chief commercial officer at digital health company Noom, shared just how dramatically these drugs are influencing employment decisions. GLP-1 medications have revolutionized obesity treatment, delivering substantial weight loss for millions of Americans. But their high price tags have triggered what benefits experts describe as a “cost cycle,” posing a serious threat to the sustainability of employer healthcare budgets.Jennifer Jones, a clinical solutions architect at Noom and registered dietitian, outlined the financial stakes during the session. “Members that have obesity, their overall health care costs can be up to six times higher than someone that’s just overweight,” noting obesity's connection to more than 16 chronic conditions. With obesity rates exceeding 42% nationally and projected to surpass 50% within five years, employers face mounting pressure to act. Traditional approaches have proven inadequate. “What we’ve been doing isn’t working,” Jones said.Perhaps no one understands the frustrations of accessing these medications better than Fair himself. Despite having a prescription for two years, he was only able to obtain his GLP-1 medication for seven months total and never for more than two consecutive months. Each time, the same obstacles emerged, the pharmacy was out of stock, prior authorization created lengthy delays, or the medication simply vanished from shelves by the time approvals came through. His frustrating cycle mirrors the experience of countless patients nationwide.The root cause of these shortages may surprise those unfamiliar with pharmaceutical economics. Pharmacies are losing money on every GLP-1 prescription they fill. “We’ve even talked to the head of pharmacies at major major corporations that say, ‘I should just staple a $20 bill to the script when I send it out the door, because that’s what I’m losing every time,’" Fair said. This financial reality has led many pharmacies to avoid stocking these medications entirely.Kelly Bourdet, journalist and founder of Apparata Media, moderated the discussion with Fair and Jones of Noom (photo by From Day One)Even when patients successfully obtain these medications, the lack of comprehensive support threatens their efficiency in the patient’s daily life. Jones described what the company calls the “GLP-1 care gap,” the void between receiving a prescription and achieving sustainable weight loss.“When people have that first script, and they get that medication, that’s often the end point of the interaction with the healthcare system,” said Jones. Without guidance on nutrition, exercise, and side effect management, many patients discontinue treatment prematurely.  Often, patients fall prey to a faulty system, regaining weight and potentially ending up less healthy than before.Research presented during the session suggests that combining medication with behavioral support yields approximately 40% greater weight loss than medication alone. Patients receiving comprehensive support were also 1.6 times more likely to successfully taper off the medication while maintaining their weight loss.To address these challenges, some employers are exploring alternative coverage strategies. Noom’s approach involves separating GLP-1 medications from traditional pharmacy benefit management and handling them as a distinct supplemental benefit. This structure offers more flexibility and potentially lower costs, about $200 less per monthly prescription after rebates, says Fair.This model allows employers to customize their contribution levels, perhaps covering 25, 50, or 75% of medication costs. By guaranteeing medication delivery within five days through specialty pharmacy networks, access issues that plague traditional distribution channels are directly addressed.Noom reports a 4.1 fold return on investment over two years when implementing comprehensive healthcare approaches, achieved through careful patient selection, early identification of non-responders, and supporting appropriate candidates in tapering off medications.Unlike providers who assume indefinite GLP-1 use, Noom has developed protocols that help suitable candidates successfully transition off these expensive medications. Jones reported that approximately 30 to 35% of patients, particularly those experiencing situational weight gain, can maintain their weight loss after tapering, when given proper support.“I don’t know a lot of people, honestly, that want to be on medication for the rest of their life,” Jones said. Through Noom's four-month tapering protocols and continued access to coaching, nutrition guidance, and exercise programs, patients are 1.6 times more likely to successfully maintain their weight without medication compared to those who stop abruptly, Jones says. This approach not only addresses patient preferences but significantly reduces long term costs for employers.As more GLP-1 medications approach market approval, including oral formulations that could broaden access for injection-averse patients, employers must develop sustainable strategies. The speakers emphasized that successful programs require more than just coverage decisions, they demand comprehensive approaches that treat obesity as the complex chronic condition it is. As these medications reshape the landscape of workplace health benefits, the challenge isn’t simply whether to provide coverage, but how to do so in ways that deliver lasting value for both employees and organizations.Editor’s note: From Day One thanks our partner, Noom, for sponsoring this webinar. Chris O’Keeffe is a freelance writer with experience across industries. As the founder and creative director of OK Creative: The Language Agency, he has led strategy and storytelling for organizations like MIT, Amazon, and Cirque du Soleil, bringing their stories to life through established and emerging media.(Photo by Alones Creative/iStock)

Christopher O'Keeffe June 12, 2025